Showing 20 of 20 recruiting trials for “Acute promyelocytic leukemia”
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
👨⚕️ ZhangBiao Long, Doctor, Department of Hematology, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road📍 1 site📅 Started Feb 2025View details ↗
Revumenib in Combination With 7+3 + Midostaurin in AML
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
RecruitingNCT06439199 ↗
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
👨⚕️ Jianxiang Wang, M.D., Hematology Hospital of the Chinese Academy of Medical Sciences📍 6 sites📅 Started Jun 2024View details ↗
Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia
👨⚕️ Eduardo M Rego, MD PhD, Instituto do Cancer do Estado de Sao Paulo📍 1 site📅 Started Oct 2023View details ↗
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
👨⚕️ Huiying Qiu, PhD, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Mar 2023View details ↗
Optimum Induction Therapy of Low-risk APL
👨⚕️ Xiaolu Zhu, Doctor, Peking University People's Hospital📍 1 site📅 Started Jan 2023View details ↗
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
👨⚕️ Seth Karol, MD, St. Jude Children's Research Hospital📍 89 sites📅 Started Oct 2022View details ↗
RecruitingNCT04897490 ↗
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
👨⚕️ María José Mela Osorio, Dr., Grupo Argentino de Tratamiento de la Leucemia Aguda📍 6 sites📅 Started Mar 2021View details ↗
Frontline Oral Arsenic Trioxide for APL
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
👨⚕️ Fanco Locatelli, Prof, Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome📍 31 sites📅 Started Oct 2019View details ↗
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →